Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649

References

• Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–881.
   PubMed Web of Science ®Google Scholar
• Haag GM, Zoernig I, Hassel JC, et al. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018;90:122–129.
   PubMed Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15(19):6225–6231.
   PubMed Web of Science ®Google Scholar
• Perez SA, Anastasopoulou EA, Tzonis P, et al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother. 2013;62(10):1599–1608.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-γ–mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540–3551.
   PubMed Web of Science ®Google Scholar
• Chen S, Li J, Li Q, et al. Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother. 2016;12(10):2491–2500.
   PubMed Web of Science ®Google Scholar
• Li JF, Niu YY, Xing YL, et al. A novel bispecific c-MET/CTLA-4 antibody targeting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer. Biosci Rep. 2019;39(5):BSR20171278.
   PubMed Web of Science ®Google Scholar
• Koopmans I, Hendriks D, Samplonius DF, et al. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. Oncoimmunology. 2018;7(8):e1466016.
   PubMed Web of Science ®Google Scholar
• Everett KL, Kraman M, Wollerton FP, et al. Generation of Fcabs targeting human and murine LAG-3 as building blocks for novel bispecific antibody therapeutics. Methods. 2019;154:60–69.
   PubMed Web of Science ®Google Scholar
• Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated co-stimulation in T-cell activation and survival. Crit Rev Immunol. 2009;29(3):187–201.
   PubMed Web of Science ®Google Scholar
• Lai C, August S, Albibas A, et al. OX40+ regulatory T cells in cutaneous squamous cell carcinoma suppress effector T-cell responses and associate with metastatic potential. Clin Cancer Res. 2016;22(16):4236–4248.
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Zhang J, et al. OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol Cell Biol. 2014;92(6):475–480.
   PubMed Web of Science ®Google Scholar
• Montler R, Bell RB, Thalhofer C, et al. OX40, PD‐1 and CTLA‐4 are selectively expressed on tumor‐infiltrating T cells in head and neck cancer. Clin Transl Immunology. 2016;5(4):e70.
   PubMedGoogle Scholar
• Weixler B, Cremonesi E, Sorge R, et al. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. Oncotarget. 2015;6(35):37588.
   PubMedGoogle Scholar
• Vetto JT, Lum S, Morris A, et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg. 1997;174:258–265.
   PubMed Web of Science ®Google Scholar
• Ramstad T, Lawnicki L, Vetto J, et al. Immunohistochemical analysis of primary breast tumors and tumor- draining lymph nodes by means of the T-cell costimulatory molecule OX-40. Am J Surg. 2000;179:400–406.
   PubMed Web of Science ®Google Scholar
• Petty JK, He K, Corless CL, et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). Am J Surg. 2001;183:512–518.
   Web of Science ®Google Scholar
• Ladányi A, Somlai B, Gilde K, et al. T-Cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res. 2004;10:521–530.
   PubMed Web of Science ®Google Scholar
• Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune stimulating target in late stage cancer patients. Cancer Res. 2013;73:7189–7198.
   PubMed Web of Science ®Google Scholar
• Ellmark P, Furebring C, Norlén P, et al. Alligator bioscience BA, Sweden. Bispecific antibody against OX40 and CLTA-4. International Patent WO2018202649A1. 2018 Nov 8.
   Google Scholar
• Liu YJ, Voo KS, Bover L, et al. University of Texas, USA. Anti-OX40 antibodies and methods of using the same. United States patent US 9,163,085. 2015 Oct 20.
   Google Scholar
• Liu YJ, Voo KS, Bover L, et al. University of Texas, USA. Anti-OX40 antibodies and methods of using the same. United States patent US 9,695,246. 2017 Jul 04.
   Google Scholar
• Liu YJ, Voo KS, Bover L, et al. University of Texas, USA. Anti-OX40 antibodies and methods of using the same. United States patent US 10,196,450. 201. Feb 05.
   Google Scholar
• Wilson NS, Waight JD, Underwood DJ, et al. Genus Inc, memorial sloan-kettering cancer center, Ludwig Institute fro Cancer Research Ltd, USA. Anit-OX40 antibodies, anti-GITR antibodies, and methods of use thereof. International patent WO2018089628. 2018 May 17.
   Google Scholar
• Simons PJ, Boon L. Biocerox Products B.V., Netherlands & Janssen Pharmaceuticals, Inc., USA. Anti-CD134 (OX40) antibodies and uses thereof. United States patent US 9,475,880. 2016 Oct 25.
   Google Scholar
• Cai Z, Chakraborty I, Garcia MM, et al. Bristol-Myers squibb Co. Antibodies against OX40 and uses thereof. United States patent US 9,644,032. 2017 May 09.
   Google Scholar
• Hammond SA, Oberst M, Du Q, et al. Medimmune, USA. Method of treating cancer with humanized anti-OX40 antibodies. United States patent US 10,150,815. 2018 Dec 11.
   Google Scholar
• Lawson ADG, Nesbitt AM, Popplewell AG UCB Pharma, Belgium. Antibody molecules having specificity for human OX40. United States patent US 8,614,295. 2013 Dec 24.
   Google Scholar
• Harding FA AbbVie Biotherapeutics Inc., USA. Anti-OX40 antibodies and their uses. United States patent US 10,040,864. 2018 Aug 07.
   Google Scholar
• Zhu Y, Liao Z, Pytela R. Spring Bioscience Corp., USA. Anti-OX40 antibodies and diagnostic uses thereof. United States patent US2018208666. 2018 Jul 26.
   Google Scholar
• Attinger A, Blein S, Back JA, et al. Glenmark Pharmaceuticals SA, Switzerland. Antibodies that bind to OX40 and their uses. United States patent US 8,748,585. 2014 Jun 10.
   Google Scholar
• Kvarnhammar AM, Veitonmäki N, Hägerbrand K, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J Immunother Cancer. 2019;7(1):103.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018 Dec 20. Identifier NCT03782467, ATOR-1015 First-in-human Study. Available from: https://clinicaltrials.gov/ct2/show/NCT03782467?term=NCT03782467&rank=1
   Google Scholar
• Johnson LS, Chichili GR, Shah K, et al. Macrogenics Inc, USA. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof. International patent WO2017106061. 2017 Jun 22.
   Google Scholar
• Xue T, Xiao L, Liu D, et al. Sichuan Kelun Biotech Biopharmaceutical Co. Ltd, China. Recombinant bispecific antibody. International patent WO2019042153. 2019 March 07.
   Google Scholar
• Yang S, Yang S, China. Method for preparing PD-1/CTLA-4 bispecific antibody and use thereof. International patent WO2017128534. 2017 Aug 03.
   Google Scholar
• Saha S, Roix JJ, Welsch D Biomed Valley Discoveries Inc., USA. Bispecific antibodies. United States patent US2016145355. 2016 May 26.
   Google Scholar
• Cai Z, Chen Y Shanghai Kanda Biotechnology Co. Ltd. China. Bispecific coupled antibody, preparation method and application thereof. United States US2019048080. 2019 Feb 14.
   Google Scholar
• Ellmark P, Fritzell S, Furebring C Alligator Bioscience AB. Sweden. Bispecific polypeptides to GITR and CTLA-4. International patent WO2018091739. 2018 May 24.
   Google Scholar
• Zhou Y, Zhang C, Guo J Shanghai CO Guojian pharmaceutical Co. Ltd., China. Anti-GITR/CTLA-4 bispecific antibody, preparation method and application thereof. China patent CN105669867, 2016 Jun 15.
   Google Scholar
• Ellmark P, Norlén P, Dahlén E, et al. Alligator bioscience AB. Sweden. Bispecific antibodies directed against OX40 and a tumor-associated antigen. European patent EP3478720. May 08.
   Google Scholar